What does the future hold for drug formulation in 2025?
Supported by:
25 September 2025
2:00pm
Shares
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
During this virtual panel, industry experts will explore the latest innovations and major challenges of drug formulation in the pharmaceutical industry.
Formulation of medicines requires the expert combination of drug substances and excipients to develop safe pharmaceuticals that meet the needs of patients worldwide, both in an individualised treatment capacity or for broader patient populations. Types of drug formulation can vary and include solid dosage forms such as tablets, as well as powdered and liquid formulations.
In this session, panellists will share their expertise on the development of efficient and safe drug formulations. They will explore the latest advances, benefits offered by technology, impact of regulatory compliance and solutions to obstacles in the sector.
Key learning points:
- Discover the latest advances being used by drug formulators in the pharmaceutical industry in 2025
- Learn about approaches that can support manufacturers, ensure optimal product quality and aid patient compliance
- Hear from industry experts and find out how to overcome key challenges in delivery, administration and drug development.
Secure your seat – register now!
OUR SPEAKER
Dr Slobodanka Dina Manceva PhD, Associate Director at Teva Pharma, has spent 20 years working in drug product development for both the early and late stage of the process. She has experience working on a broad range of biologic modalities. Her expertise lies in all DPD activities, as well as in development of high and ultra-high protein DP formulations, high throughput assay development and lab digitalisation including but not limited to artificial intelligence (AI) and machine learning (ML). Her interest is to increase productivity and enable faster delivery of lifesaving drugs to patients.
FAQs
FAQs
Is the panel discussion free?
Yes – there is no charge to watch the panel discussion, either live or on-demand.
When will the panel discussion take place?
25 September at 3pm BST.
Can I watch it later?
The panel discussion will become available to watch on-demand shortly after the live webinar takes place.
What are the benefits of attending live?
You’ll be able to ask the speakers your questions, which will be answered live in the Q&A towards the end of the session.
How long will the panel discussion be?
This panel discussion will last up to an hour.
What do I need to watch this panel discussion?
All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.
